Drug Approval | August 20, 2022
DCGI approves AstraZeneca 's Olaparib film-coated tablets
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Deputy Mayor from Addis Ababa (Ethiopia) battled out a rare laryngeal cancer at Yashoda Hospitals Hyderabad
One of the most advanced cancer care centres in the state of Odisha, it is equipped with the latest technology and a highly experienced multi-disciplinary team of oncologists
Onco Care Plus is available at just INR 399 per month, and provides services like free doctor consultation, 15% off on cancer treatment costs, 25% off for diagnostic tests, free nutrition plans, among many more
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
The objective behind introducing this extraordinary digital campaign is to spread awareness among Gen X and Z for the need of breast self-examination
Approximately five kg tumor was removed in the eight-hour long complicated surgery
Subscribe To Our Newsletter & Stay Updated
